Novartis, Sandoz Family Foundation
Switzerland-based pesticides maker Syngenta said on Wednesday that it has acquired a repository of natural compounds and ...
The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate ...
Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...
The Trump administration, perhaps surprisingly, chose to defend the legality of the Inflation Reduction Act’s (IRA’s) drug ...
Emasan AG is offering around 26.5M shares in Swiss Novartis (NVS) through Goldman Sachs, potentially raising $3B, Pablo Mayo Cerqueiro of ...
FoRx Therapeutics appoints Dr. Jens Wurthner, PhD, as Chief Medical Officer and reports progress toward IND submission by mid ...
Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...
J.P. Morgan analyst Richard Vosser maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF95.00.
Prior to this announcement, Novartis' dividend was comfortably covered by both cash flow and earnings. This indicates that ...
Novartis commits $7.5 million to the "Blitz the Barriers" campaign, aiming to raise awareness and encourage early testing for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback